Seoulin Bioscience Company Limited operates within the Commercial physical research sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Seoulin Bioscience Company Limited with three other
companies in this sector in South Korea:
sales of 21.70 billion Korean Won [US$19.19 million]
(22.21 billion Korean Won [US$19.63 million]
of which 52%
was Biotechnology), and
Medipost Co Ltd
(28.65 billion Korean Won [US$25.33 million]
of which 55%
was Umbilical Cord Blood).
During the year ended December of 2016, sales at
Seoulin Bioscience Company Limited were 44.89 billion Korean Won (US$39.68 million).
increase of 7.8%
versus 2015, when the company's sales were 41.63 billion Korean Won.
Sales of Healthcare saw an increase
that was more than double the company's growth rate: sales were up
112.2% in 2016, from
1.17 billion Korean Won to 2.49 billion Korean Won.